Cullen Frost Bankers Inc. Has $8.52 Million Stock Holdings in Novo Nordisk A/S $NVO

Key Points

• Cullen Frost Bankers Inc. increased its Novo Nordisk stake by 45.1% in the fourth quarter, buying 52,039 additional shares and bringing its total holding to 167,422 shares valued at about $8.52 million.
• Several other institutional investors also adjusted their positions, and hedge funds now own 11.54% of Novo Nordisk’s stock, indicating continued institutional interest in the company.
• Recent news flow has been mixed but mostly constructive: Novo Nordisk saw positive updates on obesity-drug data and earnings estimates, though competition from Eli Lilly and other rivals remains a significant overhang.

Cullen Frost Bankers Inc. increased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 45.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 167,422 shares of the company's stock after buying an additional 52,039 shares during the quarter. Cullen Frost Bankers Inc.'s holdings in Novo Nordisk A/S were worth $8,518,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Creative Financial Designs Inc. ADV grew its position in Novo Nordisk A/S by 640.5% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 1,170 shares of the company's stock worth $60,000 after buying an additional 1,012 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Novo Nordisk A/S by 1.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 468,869 shares of the company's stock worth $23,856,000 after purchasing an additional 5,929 shares during the period. Profund Advisors LLC lifted its stake in Novo Nordisk A/S by 162.5% during the fourth quarter. Profund Advisors LLC now owns 23,210 shares of the company's stock worth $1,181,000 after purchasing an additional 14,367 shares during the period. Auxano Advisors LLC lifted its stake in Novo Nordisk A/S by 6.5% during the fourth quarter. Auxano Advisors LLC now owns 49,904 shares of the company's stock worth $2,539,000 after purchasing an additional 3,064 shares during the period. Finally, Evergreen Wealth Management LLC bought a new position in Novo Nordisk A/S during the fourth quarter worth about $234,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Deutsche Bank said Novo Nordisk remains cautiously optimistic on its key cagrisema obesity study, suggesting the upcoming RD11 readout could outperform the disappointing prior trial and potentially improve investor sentiment. Novo Nordisk cautiously optimistic on key GLP-1 obesity study, says Deutsche Bank
• Positive Sentiment: Recent Wegovy data showed strong weight-loss efficacy, better physical function, and favorable body-composition results, while oral Wegovy also compared well with Eli Lilly’s oral GLP-1 candidate on weight loss, tolerability, and patient preference. How New Wegovy Obesity Trial Data At Novo Nordisk CPSE: NOVO B Has Changed Its Investment Story
• Positive Sentiment: Analysts at Erste Group raised FY2026 and FY2027 EPS estimates for Novo Nordisk, signaling slightly better earnings expectations and some underlying confidence in the business outlook.
• Positive Sentiment: Denmark’s 1.9% GDP growth was boosted by pharmaceutical strength linked to Novo Nordisk, underscoring the company’s continued importance and strength in its core market. Denmark GDP Jumps 1.9% as Pharma Sector Drives Growth
• Neutral Sentiment: Novo Nordisk continues to advance additional obesity-maintenance and cagrilintide studies, which keeps its pipeline active but does not yet change the near-term earnings picture. Novo Nordisk’s AMAZE 12 Trial: Next Wave in Obesity Maintenance Drugs
• Neutral Sentiment: Novo Nordisk is also expanding beyond obesity through a Parkinson’s program transfer and other strategic moves, but these are longer-term developments with limited immediate stock impact. Novo Nordisk Expands Parkinson's Bet With AI Partner And Upside Potential
• Negative Sentiment: Eli Lilly’s encouraging oral GLP-1 results highlight intensifying competition in the obesity-pill market, which could pressure Novo Nordisk’s future market share and pricing power. From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook (NVO)
• Negative Sentiment: Other competitors, including Viking Therapeutics, are also developing oral weight-loss pills, adding to the competitive overhang on Novo Nordisk’s GLP-1 franchise. Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $45.07 on Thursday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The firm has a 50 day moving average of $40.05 and a 200-day moving average of $46.51. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $201.23 billion, a P/E ratio of 10.58, a price-to-earnings-growth ratio of 3.94 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion during the quarter. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, February 23rd. BMO Capital Markets restated a "market perform" rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Morgan Stanley upgraded shares of Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price target for the company in a research note on Tuesday, March 3rd. JPMorgan Chase & Co. restated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Finally, Citigroup restated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.